Shenogen has entered into an exclusive collaboration and licensing agreement with Shanghai BioArdis and BioArdis for the development and commercialization of BioArdis' novel FGFR4 (fibroblast growth factor receptor 4) kinase inhibitor, BIO-1262/SNG-203, either as monotherapy or combination therapy in Mainland China, Hong Kong, Macau and Taiwan.
Vir Biotechnology and Alnylam Pharmaceuticals, Inc. announced an expansion to their broad multi-target existing collaboration for the development and commercialization of RNAi therapeutics for infectious diseases, including SARS-CoV-2, the virus that causes the disease COVID-19.
Novartis has unveiled plans to commence a clinical trial of Jakavi (ruxolitinib) in severe COVID-19 patients and establish an international compassionate use programme.
Citius Pharmaceuticals has entered into an exclusive six-month option agreement with Novellus subsidiary to licence novel stem-cell therapy for acute respiratory distress syndrome (ARDS) associated with COVID-19, the disease caused due to the novel coronavirus SARS-CoV-2.
Tsinghua University has joined forces with 3rd People’s Hospital of Shenzhen and Brii Biosciences (Brii Bio) to develop neutralising antibodies against COVID-19 (novel coronavirus).
VBI Vaccines, a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced a collaboration with the National Research Council of Canada (NRC), Canada’s largest federal research and development organization, to develop a pan-coronavirus vaccine candidate, targeting COVID-19, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS).
Eli Lilly has entered into a potential $880m research deal with Sitryx to discover and develop new immunometabolic medicines.
Aptorum Group has joined forces with Covar Pharmaceuticals for studying the use of three repurposed drug candidates for the treatment of novel coronavirus (COVID-19).
Sanofi’s vaccines global business unit Sanofi Pasteur has collaborated with Translate Bio for the development of a novel messenger RNA (mRNA) vaccine for COVID-19, the disease resulted due to the novel coronavirus SARS-CoV-2.
Novartis and a consortium of life sciences companies have collaborated with Bill & Melinda Gates Foundation (BMGF) to advance the development, manufacture and delivery of vaccines, diagnostics and treatments for COVID-19, the disease resulted due to the novel coronavirus SARS-CoV-2.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.